Biotech Values

[Rocky3]

JNJ earnings before the bell tomorrow. Will provide Olysio Q3 sales (and maybe some color on outside US ["OUS"] sales for Q4 and '15). I will mostly be interested in Q3 sales OUS in order to guess at Sovaldi Q3 sales OUS. Script numbers in US for Olysio have held up much better than Sovaldi from heights - scripts for Sovaldi in Q3 were down ~25% and Olysio scripts were up slightly. Clearly, since the only use of Olysio has been with Sovaldi, the percentage use of the combination has gone up significantly. Looks to be about 40%+ now.

Will be interesting to follow both US and OUS sales of Olysio in Q4 and especially in 15Q1. I would expect US sales almost to disappear by 15Q1, but think that OUS might still be rising then since there seems to such a huge delay in the pick of approved sales OUS (in the EU especially).